Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Long After Achieving Hbsag Seroconversion: A Need for an Improved Hepatitis B Virus DNA AssayShe-Yan Wong1Xiangdong David Ren2Hie-Won Hann1,3*
- *Corresponding Author:
- Hie-Won Hann
Liver Disease Prevention Center, Division of Gastroenterology and Hepatology
Department of Medicine, Jefferson Medical College
Thomas Jefferson University Hospital, USA
Tel: 1-215-955- 5806
E-mail: [email protected]
Received Date: July 25, 2013; Accepted Date: August 19, 2013; Published Date: August 21, 2013
Citation: Wong SY, Ren XD, Hann HW (2013) Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Long After Achieving Hbsag Seroconversion: A Need for an Improved Hepatitis B Virus DNA Assay. Clin Microbial 2:127. doi: 10.4172/2327-5073.1000127
Copyright: © 2013 Wong SY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The ultimate goal of antiviral treatment is prevention of hepatocellular carcinoma (HCC). Currently the end point of successful antiviral treatment for patients with chronic hepatitis B is to achieve HBsAg loss or HBsAg seroconversion. We report two patients who successfully developed anti-HBs with or without antiviral therapy and yet developed HCC. Initial commercial assay showed negative HBV DNA for both patients. However, they were found to have detectable HBV DNA by a new laboratory-developed HBV DNA assay. These cases show that patients with HBsAg seroclearance continue to be at risk for HCC and surveillance for HCC should be continued. The diagnosis of occult hepatitis B with an improved HBV DNA assays is also necessary as it is important for treatment for chronic HBV and prevention of HCC.